We are Methyl chloroacetate CAS:96-34-4 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
CAS No: 96-34-4
Product Name: Methyl chloroacetate
Density: 1.2±0.1 g/cm3
Boiling Point: 132.2±8.0 °C at 760 mmHg
Melting Point: -33 °C
Molecular Formula: C3H5ClO2
Molecular Weight: 108.524
Flash Point: 51.7±0.0 °C
Exact Mass: 107.997810
Vapour density: 3.8 (vs air)
Vapour Pressure: 9.0±0.2 mmHg at 25°C
Index of Refraction: 1.401
Water Solubility: 28 g/L (20 ºC)
Appearance: Colorless transparent liquid
Methyl monochloroacetate: ≥99.0%
Free acid: ≤0.2%
Methyl dichloroacetate: ≤0.5%
Intermediates of Omethoate CAS: 1113-02-6.
Intermediates of Dimethoate CAS: 60-51-5.
In pesticides, it is mainly used in the synthesis of the pesticides dimethoate and oxymethoate intermediates, thiophosphanate, thiophosphanate, and chloroacetophenamine. In addition, it is also used as an organic synthetic raw material, also used in medicine and bonding Preparation of surfactants and surfactants can also be used as a solvent.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.2'-Deoxyadenosine hydrate CAS:16373-93-6 This includes chemical APIs.[diacetyloxy(propyl)silyl] acetate Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.Gallic acid CAS:149-91-7 The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.